RTI Biologics has implemented several organizational and leadership changes as part of a companywide initiative to optimize operations, improve cost effectiveness, and provide superior customer service, the company announced.
Effective immediately, the following key changes in RTI's leadership structure have taken place:
- Robert Jordheim has joined the company as executive vice president and chief financial officer.
- Thomas F. Rose, executive vice president, has transitioned from the role of chief financial officer to chief operations officer.
- Caroline Hartill has been named executive vice president and chief scientific officer.
- Roger W. Rose has been named executive vice president and chief commercial officer.
All will report to Brian K. Hutchison, RTI chairman and chief executive officer, and together with him serve as the company's executive management committee. The executive management committee oversees all aspects of the company and develops and implements corporate strategy.
"These changes to our leadership team correspond with realignment in our organizational structure," Hutchison said in a press release. "As we are moving through our initiative to improve operational and cost efficiencies while intensifying focus on customer service, we have grouped business and administrative departments under members of the executive management committee."
Copyright © 2010 DrBicuspid.com
